<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        55-249-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        APO-ATORVASTATIN 20 mg Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATORVASTATIN CALCIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        22.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX INC. (SIGNET SITE)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>APO-ATORVASTATIN belongs to the class of medicines known as &quot;statins&quot;, more specifically called HMG-CoA reductase inhibitors. HMG-CoA reductase is an enzyme involved in regulating cholesterol levels in your body. Statins are used along with changes to exercise and diet to help control the amount of cholesterol produced by the body.</p><p>Your doctor has prescribed these pills to help lower your cholesterol or other fats in the blood (such as triglycerides) and to prevent cardiovascular disease such as heart attacks. High levels of cholesterol and other fats can cause heart disease by clogging the blood vessels that feed blood and oxygen to the heart.</p><p>Children 10-17 years old with heterozygous familial hypercholesterolemia (high cholesterol inherited from one of the parents) and a family history of cardiovascular disease or 2 or more risk factors of cardiovascular disease, as determined by your doctor, can also benefit from taking APO-ATORVASTATIN.</p><p>APO-ATORVASTATIN is just part of the treatment your doctor will plan with you/your child to help keep you healthy. Depending on your/your child&rsquo;s health and lifestyle, your doctor may recommend:</p><ul><li>a change in diet to &nbsp;control weight and &nbsp; reduce cholesterol, reduce intake of saturated fats and increase fiber</li><li>exercise that is right for you/your child</li><li>quitting smoking or avoiding smoky places</li><li>giving up alcohol</li></ul><p>Follow your doctor&#39;s instructions carefully.</p><p>APO-ATORVASTATIN can help your body by:</p><ul><li>Decrease LDL (bad) cholesterol, triglyceride &nbsp;levels and other lipids/fats in the blood</li><li>Increase HDL (good) cholesterol.</li><li>Decrease &nbsp; the Total Cholesterol HDL-Cholesterol Ratio (TC:HDL-C Ratio). This ratio represents the balance between bad and good cholesterol.</li></ul><p>APO-ATORVASTATIN also reduces the risk of heart attacks and strokes in people with multiple risk factors for coronary heart disease such as high blood pressure and diabetes. When used by people who have suffered a heart attack in the past. &nbsp;APO-ATORVASTATIN reduces the risk of having another heart attack.</p><p>APO-ATORVASTATIN is only available by prescription after seeing a doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>a- Do not take APO-ATORVASTATIN if you</strong></u></p><ul><li>are/is allergic to any ingredient of this medication (see what the medicinal ingredient is and what the important non medicinal ingredients are).</li><li>have active liver disease or unexplained increases in liver enzymes.</li><li>have thyroid problems</li><li>have had a stroke or a mini stroke (TIA)</li><li>regularly drink three or more alcoholic drinks daily</li><li>are taking any other cholesterol &nbsp;lowering medication such as fibrates (gemfibrozil, &nbsp;fenofibrate), niacin or ezetimibe</li><li>have a family history of muscular disorders</li><li>had any past problems with the muscles (pain, tenderness), after using an HMG-CoA reductase inhibitor (&quot;stalin&quot;) such as atorvastatin (APO&shy;-ATORVASTATIN), fluvastatin (Lescol), lovastatin (Mevacor), &nbsp;pravastatin (Pravacol), rosuvastatin (Crestor) or simvastatin (Zocor) or have developed an allergy or intolerance to them</li><li>have kidney or liver problems</li><li>have diabetes (as the dosage of APO-ATORVASTATIN may need to be adjusted)</li><li>have undergone &nbsp;surgery or other tissue injury</li><li>do excessive &nbsp;physical exercise</li></ul><p>&nbsp;</p><p><u><strong>b- Take special care with APO-ATORVASTATIN</strong></u></p><p>Tell your doctor if you/your child have any muscle pain, tenderness, soreness or weakness &nbsp;during treatment with APO-ATORVASTATIN.</p><p>APO-ATORVASTATIN was studied in boys and girls (girls who already started their period) 10-17 years at a dose of 10 and 20 mg. APO-ATORVASTATIN has not been studied in pre-pubertal patients or patients younger than 10 years of age. Adolescent girls should discuss with their doctor the potential hazards to the fetus and the importance of birth control while on APO&shy; ATORVASTATIN therapy.</p><p>&nbsp;</p><p><u><strong>c- Taking APO-ATORVASTATIN with other medicines, herbal or dietary supplements</strong></u></p><p>As with most medicines, interaction with other drugs is possible. Tell your doctor or pharmacist if you are taking any other medications, including prescription, non&shy; prescription and natural health products.&nbsp;</p><p>In particular, these drugs may interact with APO-ATORVASTATIN:</p><ul><li>corticosteroids &nbsp;(cortisone-like medicines)</li><li>cyclosporine (SANDIMMUNE&reg;)</li><li>gemfibrozil ( LOPID&reg;)</li><li>fenofibrate (LIPIDIL MICRO&reg;) or bezafibrate</li><li>(BEZALIP&reg;)</li><li>lipid-lowering&nbsp;doses of niacin (nicotinic acid)</li><li>erythromycin, clarithromycin or azole antifungal agents (ketoconazole &nbsp;or itraconazole)</li><li>nefazodone (SERZONE&reg;)</li><li>indinavir sulfate (CRIXIVAN&reg;), nelfinavir mesylate</li><li>(VIRACEPT&reg;), ritonavir (NORVIR&reg;), saquinavir mesylate (INVIRASE&trade;)</li><li>digoxin&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;</li><li>diltiazem</li><li>efavirenz, &nbsp;rifampin&nbsp;&nbsp; &nbsp;</li><li>antacids (frequent use) and&nbsp; APO-ATORVASTATIN should be taken 2 hours apart grapefruit juice especially if ingesting upwards of 1.2 liters of grapefruit juice at once.</li></ul><p>&nbsp;</p><p><u><strong>d- Taking APO-ATORVASTATIN with food and drink</strong></u></p><p>It does not matter if APO-ATORVASTATIN is taken with food or without food, but it should not be taken with grapefruit juice. It should be taken 2 hours apart grapefruit juice especially if ingesting upwards of 1.2 liters of grapefruit juice at once.</p><p>&nbsp;</p><p><u><strong>e- Pregnancy and breast-feeding</strong></u></p><p>- Tell your doctor if you are/she is pregnant, intend to become pregnant. Cholesterol compounds are essential elements for the development of a fetus. Cholesterol-lowering drugs can harm the fetus. Females of child-bearing age should discuss with their doctor the potential hazards to the fetus and the importance of birth control methods. APO-ATORVASTATIN should not be used by pregnant women. &nbsp;If you/your child become pregnant, discontinue use immediately and discuss with your doctor.</p><p>- Tell your doctor if you are/she is breast-feeding or intend to breast-feed. &nbsp;This medicine may be present in breast milk.</p><p>&nbsp;</p><p><u><strong>f- Driving and using machines</strong></u></p><p>No or negligible influence.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>We often cannot see or feel the problems that high cholesterol causes until a lot of time has passed. That&#39;s why it is important to take these pills just as prescribed. You/your child and your doctor will be watching your/your child&#39;s cholesterol levels to get them down to a safe range. Here are some important tips.</p><ul><li>Follow the plan that you/your child and your doctor make for diet, exercise and weight control.</li><li>Take APO-ATORVASTATIN as a single dose. It does not matter if APO-ATORVASTATIN is taken with food or without food, but it should not be taken with grapefruit juice. Your doctor will usually tell you/your child to take it in the evenings.</li><li>Do not change the dose unless directed by a doctor.</li><li>If you/your child get sick, have an operation, or need medical treatment, inform your doctor or pharmacist that you/your child are taking APO&shy;ATORVASTATIN.</li><li>If you/your child have to take any other medicine&shy;prescription or non-prescription while taking APO&shy;ATORVASTATIN, talk to your doctor or pharmacist first.</li><li>If you/your child have to see a different doctor for any reason, be sure to inform him/her that you/your child are/is taking APO-ATORVASTATIN.</li><li>APO-ATORVASTATIN was prescribed for you/your child only. Don&#39;t give these pills to anyone else.</li></ul><p>&nbsp;</p><p><u><strong>How much APO-ATORVASTATIN to take</strong></u></p><p><strong>Adults:</strong></p><p>The recommended starting dose of APO&shy; ATORVASTATIN is 10 or 20 mg once daily, depending on your required LDL-C reduction. Patients who need a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of APO&shy;ATORVASTATIN is 10 to 80 mg once daily. The maximum dose is 80 mg/day.</p><p>The recommended dose of APO-ATORVASTATIN is 10 to 80 mg/day for people who have already suffered a heart attack.</p><p><strong>Children (10-17 years old):</strong></p><p>The recommended starting dose of APO-ATORVASTATIN is 10 mg/day; the maximum recommended dose is 20 mg/day.</p><p>&nbsp;</p><p><u><strong>a- If you take more APO-ATORVASTATIN than should</strong></u></p><p>There is no specific treatment for APO-ATORVASTATIN over dosage. Should an overdose occur, see your doctor right away.</p><p>In the event of over dosage, contact your doctor, hospital emergency department or regional Poison Control Centre.</p><p>&nbsp;</p><p><u><strong>b- If you forget to take APO-ATORVASTATIN</strong></u></p><p>If you/your child miss taking a pill, take it as soon as possible. But if it is almost time for the next dose, skip the missed dose and just take the next dose. Don&#39;t take a double dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Most people do not have any problems with side effects when taking this medicine. However, all medicines can cause unwanted side effects. Check with your doctor or pharmacist promptly if any of the following persist or become troublesome:</p><p>&bull; constipation/diarrhea/gas&nbsp;&nbsp; &nbsp;&bull; depression (in children)<br />&bull; headache&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; skin rash<br />&bull; stomach &nbsp;pain or upset&nbsp;&nbsp; &nbsp;&bull; vomiting or throwing up</p><p>Very rarely, a few people may suffer from jaundice, from a liver condition called hepatitis.</p><p>This is not a complete list of side effects. If you/your child notice anything unusual or any unexpected effects while taking APO-ATORVASTATIN, contact your doctor or pharmacist.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p><strong><u>SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT DO ABOUT THEM</u></strong></p></td></tr><tr><td rowspan="6"><p><strong>&nbsp;</strong><strong>Rare</strong></p></td><td rowspan="2"><p><strong>Symptom/Effect</strong></p></td><td colspan="2"><p><strong>Talk with your doctor or pharmacist</strong></p></td><td rowspan="2"><p><strong>Stop taking the drug and&nbsp;seek emergency medical assistance</strong></p></td></tr><tr><td><p><strong>Only if severe</strong></p></td><td><p><strong>In all cases</strong></p></td></tr><tr><td><p>Muscle pain that you cannot explain</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Muscle tenderness or weakness</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Generalized weakness, especially if you don&#39;t feel well</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Brownish or discoloured urine</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Always keep medicine well out of the reach of children.<br />- Keep APO-ATORVASTATIN at room temperature less than 25&deg;C, away from warm and damp places, like the bathroom or kitchen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is atorvastatin calcium propylene glycol solvate.</li><li>The other ingredients are calcium acetate, croscarmellose sodium, sodium carbonate, microcrystalline cellulose, &nbsp;magnesium stearate, colloidal silicon dioxide. hydroxypropyl methylcellulose. hydroxypropyl cellulose. &nbsp;polyethylene glycol. titanium dioxide.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tablets are available in 4 strengths: 10 mg. 20 mg. 40 mg and 80 mg. Available in blisters of 30.

APO-ATORVASTATIN 10 mg:  Each tablet contains 11 mg atorvastatin calcium propylene glycol solvate, equivalent to 10 mg free acid.  White, oval, biconvex film-coated tablets. Engraved “APO” on one side, “A10” on the other side.  

APO-ATORVASTATIN 20 mg:  Each tablet contains 22 mg atorvastatin calcium propylene glycol solvate, equivalent to 20 mg free acid.  White, oval, biconvex film-coated tablets. Engraved “APO” on one side, “ATV20” on the other side.  

APO-ATORVASTATIN 40 mg:  Each tablet contains 44 mg atorvastatin calcium propylene glycol solvate, equivalent to 40 mg free acid.  White, oval, biconvex film-coated tablets. Engraved “APO” on one side, “ATV40” on the other side.  

APO-ATORVASTATIN 80 mg:  Each tablet contains 88 mg atorvastatin calcium propylene glycol solvate, equivalent to 80 mg free acid.  White, oval, biconvex film-coated tablets. Engraved “APO” on one side, “ATV80” on the other side.

* Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>إن ابو- أتورفاستاتين ينتمي إلى فئه من الأدوية المعروفة باسم (ستاتينات), وعلى نحو أكثر تحديدا تسمى مثبطات الإنزيم المختزل لـ &quot;هيدروكسي ميثيل جلوتاريل كو إيه&quot;. الإنزيم المختزل لـ &quot;هيدروكسي ميثيل جلوتاريل كو إيه&quot; &nbsp;هو إنزيم مسئول عن تنظيم مستويات الكولسترول في الجسم. وتستخدم الاستاتينات جنبا إلى جنب مع تغييرات في ممارسة الرياضة واتباع نظم غذائية للمساعدة على التحكم في كمية الكولسترول التي ينتجها الجسم.</p><p>قد يصف طبيبك هذه الحبوب &nbsp;للمساعدة على خفض نسبة الكوليسترول أو الدهون الأخرى في الدم (مثل الدهون الثلاثية) وللوقاية من أمراض القلب والشرايين مثل الأزمات القلبية. ويمكن أن تتسبب المستويات العالية من الكوليسترول والدهون الأخر في الإصابة بأمراض القلب عن طريق انسداد الأوعية الدموية التي تمد القلب بالدم والأوكسجين.</p><p>ويمكن للأطفال ممن تتراوح أعمارهم بين 10 و 17 عاماً والذين يعانون من ارتفاع الكولسترول العائلي مختلف اللواقح )ارتفاع كوليسترول الدم الموروث من أحد الوالدين( مع تاريخ عائلي للإصابة بأمراض القلب والأوعية الدموية أو اثنان أو أكثر من عوامل الخطورة المتعلقة بأمراض القلب والأوعية الدموية، بحسب ما يحدده الطبيب المعالج، أن يستفيدوا من تناول ابو-أتورفاستاتين.</p><p>ابو-أتورفاستاتين هو مجرد جزء من العلاج الذي سوف يقوم الطبيب بوضع خطة له معك / طفلك &nbsp;للمساعدة في الحفاظ على صحتك. ووفقاً لحالتك الصحية/ حالة طفلك ونمط الحياة، قد يوصي طبيبك:</p><ul><li>بإحداث تغيير في النظام الغذائي للسيطرة على الوزن وخفض الكولسترول، والحد من تناول الدهون المشبعة وزيادة الألياف؛&nbsp;</li><li>بممارسة التمارين الرياضية المناسبة لك / طفلك؛&nbsp;</li><li>بالإقلاع عن التدخين أو تجنب أماكن الدخان؛</li><li>&bull;بالتخلي عن الكحول.</li></ul><p>اتبع تعليمات الطبيب بدقة.<br />يمكن لعقار ابو-أتورفاستاتين مساعدة جسمك في:</p><ul><li>تخفيض كوليستيرول البروتين الدهني منخفض الكثافة (الكوليستيرول الضار)، ومستويات الدهون الثلاثية والدهون الأخرى في الدم.</li><li>زيادة كوليستيرول البروتين الدهني مرتفع الكثافة (الكوليستيرول النافع).</li><li>قليل نسبة الكولسترول الكلي إلى كوليستيرول البروتين الدهني مرتفع الكثافة وتمثل هذه النسبة &nbsp;التوازن بين الكولسترول الضار والنافع.&nbsp;</li></ul><p>كما يقلل ابو-أتورفاستاتين أيضا من خطرالأزمات القلبية والسكتات الدماغية &nbsp;لدى الأشخاص الذين لديهم عوامل خطورة &nbsp;متعددة للإصابة بقصور الشرايين التاجية مثل ارتفاع ضغط الدم ومرض السكري. كما يقلل ابو- أتورفاستاتين من خطر حدوث أزمة قلبية ثانية عندما يستخدم في الأشخاص الذين قد أصيبوا بأزمات قلبية سابقة.</p><p>لا يتم الحصول على ابو- أتورفاستاتين إلا بواسطة وصفة طبية بعد زيارة الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>أ- متى يجب عدم استخدام ابو- أتورفاستاتين</strong></u></p><p>لا تتناول ابو- أتورفاستاتين إذا كان</p><ul><li>لديك/ لديه &nbsp;حساسية لأي من مكونات هذا الدواء (انظر ما هي المكونات الدوائية، وما هي المكونات غير الدوائية الهامة)</li><li>لديك مرض كبدي نشط أو زيادات غير المبررة في إنزيمات الكبد.</li><li>لديك مشاكل بالغدة الدرقية</li><li>سبقت إصابتك بسكتة دماغية أو سكتة دماغية صغيرة (تي آي إيه)</li><li>كنت عادة تشرب المشروبات الكحولية ثلاث مرات أو أكثر يومياً</li><li>تتناول أي أدوية أخرى لخفض الكولسترول &nbsp;مثل أدوية فيبرات (جيمفيبروزيل, فينوفيبرات), نياسين أو إيزيتيميب</li><li>لديك تاريخ عائلي للإصابة باعتلالات عضلية</li><li>لديك أي مشاكل سابقة في العضلات (ألم، شعور بالألم حال الضغط عليها)، بعد استخدام مثبطات الإنزيم المختزل لـ &quot;هيدروكسي ميثيل جلوتاريل كو إيه&quot; (&quot;ستاتين&quot;) مثل أتورفاستاتين (ابو- أتورفاستاتين)، فلوفاستاتين(ليسكول), لوفاستاتين(ميفاكور), برافاستاتين (برافاكول), روزيوفاستاتين (كريستور) أو سيمفاستاتين (زوكور) أو أصابتك حساسية من هذه الأدوية أو عدم تحملها</li><li>تعاني من مشاكل في الكلى أو الكبد</li><li>تعاني من مرض السكري (فقد تحتاج إلى تعديل جرعة ابو- أتورفاستاتين)</li><li>قد خضعت لعملية جراحية أو غيرها من إصابات الأنسجة&nbsp;</li><li>تقوم &nbsp;بتمارين رياضية عنيفة</li></ul><p>&nbsp;</p><p><u><strong>ب- الاحتياطات عند استخدام ابو- أتورفاستاتين</strong></u></p><p>قم بإبلاغ طبيبك إذا أصابك / &nbsp;أصاب طفلك أي ألم في العضلات أو شعور بألم حال الضغط عليها أو تقرح أو ضعف عضلي خلال فترة العلاج بعقار ابو-أتورفاستاتين.</p><p>وتمت دراسة &nbsp;ابو- أتورفاستاتين في البنين والبنات (الفتيات اللواتي بدأت دورة الحيض لديهن بالفعل) ممن تتراوح أعمارهم بين عشرة أعوام وسبعة عشر عاماً باستخدام جرعة 10 ملجم و 20 ملجم. ولكن لم يتم دراسة ابو- أتورفاستاتين &nbsp;في المرضى الذين هم في مرحلة ما قبل البلوغ أو المرضى الذين تقل أعمارهم عن 10 سنوات. وينبغي على الفتيات المراهقات مناقشة المخاطر المحتملة على الجنين وأهمية استخدام وسائل منع الحمل أثناء العلاج بعقار ابو- أتورفاستاتين مع الطبيب المعالج.</p><p>&nbsp;</p><p><u><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي ادوية اخرى او اعشاب او مكملات غذائية</strong></u></p><p>كما هو الحال مع معظم الأدوية، فمن الممكن التفاعل مع أدوية أخرى. فينبغي عليك إخبار الطبيب أو الصيدلي إذا كنت تتناول أي أدوية أخرى، بما في ذلك &nbsp;الأدوية التي يتم الحصول عليها بواسطة وصفة طبية وتلك التي يتم الحصول عليها بدون وصفة &nbsp;طبية والمنتجات الصحية الطبيعية. &nbsp;وعلى وجه الخصوص، قد تتفاعل هذه الأدوية مع &nbsp;ابو- أتورفاستاتين:&nbsp;<br />&bull; الكورتيكوستيرويدات (الأدويه الشبيهه بالكورتيزون)<br />&bull; سيكلوسبورين (ساندميون&reg;)<br />&bull; جيمفيبروزيل(لوبيد&reg;)<br />&bull; فينوفايبرات(ليبيديل مايكرو&reg;) أو بيزافيبرات (بيزاليب&reg;)<br />&bull; الجرعات المخفضة للدهون من النياسين (حمض النيكوتينيك)<br />&bull; إريثروميسين، كلاريثروميسين أو مضادات الفطريات آزول ( كيتوكونازول أو ايتراكونازول).<br />&bull; نيفازودون (سيرزون&reg;)&nbsp;<br />&bull; اندينافير سالفات(كريكسيفان&reg;), نيلفينافير ميسايلات (فيراسيبت&reg;), ريتونافير (نورفير&reg;), ساكينافير ميسيلات (انفيراس&trade;)<br />&bull; ديجوكسين&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; ديلتيازيم<br />&bull; ايفافيرنز، ريفامبين&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; مضادات الحموضة (الاستخدام المتكرر) &nbsp;<br />&bull; ينبغي تناول ابو- أتورفاستاتين بفارق ساعتان مع عصير الجريب فروت - وخاصة إذا تناول ما يزيد عن 1.2 ليتر من عصير جريب فروت في وقت واحد.</p><p>&nbsp;</p><p><u><strong>د- تناول ابو- أتورفاستاتين مع الطعام والشراب</strong></u></p><p>لا يهم إذا تم تناول ابو- أتورفاستاتين مع الطعام أو بدون طعام، ولكن لا ينبغي تناوله مع عصير جريب فروت. يجب تناول الاقراص قبل العصير بساعتين خاصة إذا تناول ما يزيد عن 1.2 ليتر من عصير جريب فروت في وقت واحد.</p><p>&nbsp;</p><p><u><strong>هـ - الحمل والرضاعة</strong></u></p><p>أخبر طبيبك إذا كنت حاملا، أو تنوين الحمل. حيث تعتبر مركبات الكولسترول عناصر أساسية لتطور الجنين. لذا فالعقاقير التي تعمل على خفض الكوليسترول يمكن أن تضر بالجنين. وينبغي على النساء اللواتي في سن الإنجاب مناقشة المخاطر المحتملة على الجنين ، وكذلك أهمية وسائل تحديد النسل مع الطبيب. &nbsp;وينبغي عدم استخدام &nbsp;ابو- أتورفاستاتين &nbsp;من قبل النساء الحوامل. فإذا أصبحت &nbsp;حاملا، فينبغي عليك التوقف عن استخدامه فورا ومناقشة ذلك مع طبيبك.</p><p>أخبر طبيبك إذا كنت ترضعين رضاعة طبيعية أو تنوين ذلك. فقد يفرز هذا الدواء في حليب الأم.</p><p>&nbsp;</p><p><u><strong>و- تأثيره على القيادة واستخدام الآلات</strong></u></p><p>لا يوجد اي تأثير.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>في كثير من الأحيان لا نستطيع أن نرى أو نشعر بالمشاكل التي يسببها ارتفاع الكوليسترول في الدم إلا بعد مرور وقت طويل. لهذا السبب من المهم أن تتناول هذه الحبوب كما هو موصوف لك بالضبط. وسوف يراقب الطبيب مستويات الكوليسترول في الدم لديك /لدى طفلك لتخفيضها إلى المستوى الآمن.وإليك بعض النصائح الهامة.</p><ul><li>اتبع الخطة التي قمت أنت/ طفلك مع الطبيب بوضعها لتنظيم التغذية وممارسة الرياضة &nbsp;وخفض الوزن.</li><li>قم بتناول ابو- أتورفاستاتين &nbsp;في جرعة واحدة. لا يهم إذا تم تناول ابو- أتورفاستاتين &nbsp;مع الطعام أو بدون طعام، ولكن لا ينبغي تناوله مع عصير جريب فروت. وعادة ما سينصحك طبيبك المعالج/ ينصح طفلك بتناوله &nbsp;في المساء.&nbsp;</li><li>لا تقدم على تغيير &nbsp;الجرعة إلا بتوجيه من الطبيب.&nbsp;</li><li>إذا مرضت /مرض طفلك أو خضعت لعملية جراحية أو احتجت للعلاج الطبي، فبادر بإبلاغ الطبيب أو الصيدلي أنك /طفلك تتناول ابو- أتورفاستاتين.</li><li>إذا كان من الضروري أن تتناول / يتناول طفلك أي دواء آخر- سواء كان من الأدوية التي تصرف بوصفة طبية أو تلك التي تصرف بدون وصفة طبية- أثناء تناولك ابو- أتورفاستاتين فينبغي عليك إبلاغ الطبيب أو الصيدلي أولا.&nbsp;</li><li>إذا توجب عليك/ على طفلك الذهاب إلى طبيب آخر لأي سبب من الأسباب فيجب التأكد من إبلاغه/ إبلاغها بأنك / طفلك تتناول/ يتناول عقار ابو- أتورفاستاتين.</li><li>إن ابو- أتورفاستاتين موصوف لك/ لطفلك فقط. لا تعطي هذه الحبوب إلى أي شخص آخر.</li></ul><p>&nbsp;</p><p><u><strong>كيفية استخدام ابو- أتورفاستاتين</strong></u></p><p><strong>الجرعة المعتادة للبالغين:</strong><br />&nbsp;&nbsp;الجرعة المبدئية الموصى بها من ابو- أتورفاستاتين هي 10 أو 20 ملجم مرة واحدة يوميا، بحسب القدر المطلوب من تخفيض كوليستيرول البروتين الدهني منخفض الكثافة لديك. فقد &nbsp;يبدأ المرضى الذين يحتاجون إلى تقليل مستوى كوليستيرول البروتين الدهني منخفض الكثافة بنسبة كبيرة (أكثر من 45%) بجرعة 40 ملجم مرة واحدة يوميا. وتتراوح جرعات ابو- أتورفاستاتين من 10 إلى 80 ملجم مرة واحدة يوميا. والجرعة القصوى هي 80 ملجم / يوم.</p><p>الجرعة الموصى بها من ابو- أتورفاستاتين هي 10 إلى 80 ملجم / يوم بالنسبة للأشخاص الذين قد أصيبوا بالفعل بأزمة قلبية.</p><p><strong>الأطفال (10-17 سنة):&nbsp;</strong></p><p>الجرعة المبدئية الموصى بها من ابو- أتورفاستاتين هي 10 ملجم / يوم، والجرعة القصوى الموصى بها هي 20 ملجم /يوم.</p><p>&nbsp;</p><p><u><strong>أ- الجرعة الزائدة</strong></u></p><p>لا يوجد علاج محدد للجرعة الزائدة من ابو- أتورفاستاتين. فإذا حدث تجاوز الجرعة، فبادر بزيارة طبيبك المعالج على الفور.</p><p>في حال تناول جرعة زائدة، عليك الاتصال بطبيبك أو قسم الطوارئ في المستشفى أو المركز الإقليمي لعلاج السموم.</p><p>&nbsp;</p><p><u><strong>ب- نسيان تناول جرعة ابو- أتورفاستاتين</strong></u></p><p>إذا نسيت / نسي طفلك &nbsp;تناول الحبوب، عليك تناولها في أقرب وقت ممكن. ولكن إذا كان وقت الجرعة التالية تقريبا ، فلا تتناول الجرعة الفائتة وتناول فقط الجرعة التالية. لا تأخذ جرعة مضاعفة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>معظم الناس لا يعانون من أية مشكلات تتعلق بالآثار الجانبية عند تناول هذا الدواء. ومع ذلك، يمكن لجميع الأدوية أن تسبب آثارا جانبية غير مرغوب فيها. وينبغي مراجعة الطبيب أو الصيدلي فورا إذا كان استمرت أي من الأعراض التالية أو أصبحت مزعجة:</p><p>- الإمساك / الإسهال / غاز&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;- اكتئاب (في الأطفال)<br />- صداع&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;- طفح جلدي<br />- آلام في المعدة أو اضطراب&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;- القيء أو التقيؤ</p><p>في حالات نادرة جدا، قد يعاني عدد قليل من الناس &nbsp;من الصفراء جراء حالة تصيب الكبد تسمى الالتهاب الكبد.&nbsp;</p><p>هذه ليست قائمة كاملة بالآثار الجانبية. فإذا لاحظت/ طفلك أي آثار غير معتادة أو غير متوقعة أثناء تناول ابو- أتورفاستاتين فعليك الاتصال بالطبيب أو الصيدلي.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p dir="RTL"><strong>الآثار الجانبية الخطيرة، ومدى تكرار حدوثها وكيفية التعامل معها</strong></p></td></tr><tr><td colspan="2" rowspan="2"><p dir="RTL"><strong>العرض/الآثر</strong></p></td><td colspan="2"><p dir="RTL"><strong>تحدث إلى الطبيب أو الصيدلي</strong></p></td><td rowspan="2"><p dir="RTL"><strong>التوقف عن تناول<br />الدواء وطلب المساعدة<br />الطبية الطارئة</strong></p></td></tr><tr><td><p dir="RTL"><strong>في الحالات الخطرة فقط</strong></p></td><td><p dir="RTL"><strong>في كل الحالات</strong></p></td></tr><tr><td rowspan="4" colspan="1"><p dir="RTL"><strong>نادرا</strong></p><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">ألم بالعضلات لا يمكنك تفسيره</p></td><td><p dir="RTL">&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL">شعور بالألم حال الضغط على العضلات أو ضعف عضلي</p></td><td><p dir="RTL">&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL">ضعف عام وخاصة إذا كنت لا تشعر أنك بصحة جيدة</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL">البول البني أو متغير اللون</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدًا عن متناول الأطفال.<br />- يحفظ ابو- أتورفاستاتين في درجة حرارة الغرفة أقل من ۲٥ درجة مئوية بعيدا عن الأماكن الدافئة والرطبة، مثل الحمام أو المطبخ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>المادة الفعالة هي مذاب أتورفاستاتين كالسيوم بروبيلين جليكول.</li><li>باقي المواد هي اسيتات الكالسيوم وكروسكارميلوز الصوديوم، كربونات الصوديوم، والسليولوز دقيق التبلر، ستيرات المغنيسيوم، ثاني أكسيد السيليكون الغروي، &nbsp;هيدروكسي بروبيل ميثيل سليلوز، هيدروكسي بروبيل السليلوز، بولي ايثيلين جليكول، وثاني أكسيد التيتانيوم.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص متوفرة في 4 تركيزات: 10 ملجم، 20 ملجم، 40 ملجم و 80 ملجم. في علب اشرطة تكون من 30 قرص.</p><ul><li>ابو- أتورفاستاتين 10 ملجم: &nbsp;كل قرص يحتوي على 11 ملجم من مذاب أتورفاستاتين كالسيوم بروبيلين جليكول تساوي 10 ملجم أتورفاستاتين. شكل الاقراص بيضاء اللون بيضاوية ومحدبة من الجانبين ومغلفة بطبقة رقيقة. منقوش عليها &quot;APO&quot; على أحد الجانبين ومنقوش &quot;A10&quot; على الجانب الآخر.&nbsp;</li><li>ابو- أتورفاستاتين 20 ملجم: &nbsp;كل قرص يحتوي على 22 ملجم من مذاب أتورفاستاتين كالسيوم بروبيلين جليكول تساوي 20 ملجم أتورفاستاتين. شكل الاقراص بيضاء اللون بيضاوية ومحدبة من الجانبين ومغلفة بطبقة رقيقة. منقوش عليها &quot;APO&quot; على أحد الجانبين ومنقوش &quot;ATV20&quot; على الجانب الآخر.</li><li>ابو- أتورفاستاتين 40 ملجم: &nbsp;كل قرص يحتوي على 44 ملجم من مذاب أتورفاستاتين كالسيوم بروبيلين جليكول تساوي 40 ملجم أتورفاستاتين. شكل الاقراص بيضاء اللون بيضاوية ومحدبة من الجانبين ومغلفة بطبقة رقيقة. منقوش عليها &quot;APO&quot; على أحد الجانبين ومنقوش &quot;ATV40&quot; على الجانب الآخر.</li><li>ابو- أتورفاستاتين 80 ملجم: &nbsp;كل قرص يحتوي على 88 ملجم من مذاب أتورفاستاتين كالسيوم بروبيلين جليكول تساوي 80 ملجم أتورفاستاتين. شكل الاقراص بيضاء اللون بيضاوية ومحدبة من الجانبين ومغلفة بطبقة رقيقة. منقوش عليها &quot;APO&quot; على أحد الجانبين ومنقوش &quot;ATV80&quot; على الجانب الآخر.</li></ul><p>* قد لا يتم تسويق كل التراكيز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9 كندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-ATORVASTATIN
Atorvastatin Calcium Tablets
10 mg, 20 mg, 40 mg and 80 mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-ATORVASTATIN 10 mg:  Each tablet contains 11 mg atorvastatin calcium propylene glycol solvate, equivalent to 10 mg free acid. White, oval, biconvex film-coated tablets. Engraved “APO” on one side, “A10” on the other side.

APO-ATORVASTATIN 20 mg:  Each tablet contains 22 mg atorvastatin calcium propylene glycol solvate, equivalent to 20 mg free acid. White, oval, biconvex film-coated tablets. Engraved “APO” on one side, “ATV20” on the other side.

APO-ATORVASTATIN 40 mg:  Each tablet contains 44 mg atorvastatin calcium propylene glycol solvate, equivalent to 40 mg free acid. White, oval, biconvex film-coated tablets. Engraved “APO” on one side, “ATV40” on the other side.

APO-ATORVASTATIN 80 mg:  Each tablet contains 88 mg atorvastatin calcium propylene glycol solvate, equivalent to 80 mg free acid. White, oval, biconvex film-coated tablets. Engraved “APO” on one side, “ATV80” on the other side.

Tablet Composition
Each tablet contains either 11 mg (or 22 mg, 44 mg or 88 mg) Atorvastatin Calcium Propylene Glycol Solvate, equivalent to 10 mg, 20 mg, 40 mg and 80 mg free acid respectively, as the active ingredient. Each tablet also contains the following non-medicinal ingredients: calcium acetate, croscarmellose sodium, sodium carbonate, microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene glycol, titanium dioxide.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-ATORVASTATIN is available in dosage strengths of 10 mg, 20 mg, 40 mg and 80 mg atorvastatin per tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>APO-ATORVASTATIN (atorvastatin calcium) is indicated as an adjunct to lifestyle changes, including diet, for the reduction of elevated total cholesterol (total-C), LDL-C, triglycerides (TG) and apolipoprotein B (apo B), the Total-C/HDL-D ratio and for increasing HDL-C; in hyperlipidemic and dyslipidemic conditions, including:</p><ul><li>Primary hypercholesterolemia (Type IIa);</li><li>Combined (mixed) hyperlipidemia (Type IIb), including familial combined hyperlipidemia, regardless of whether cholesterol or triglycerides are the lipid abnormality of concern;</li><li>Dysbetalipoproteinemia (Type III);</li><li>Hypertriglyceridemia (Type IV);</li><li>Familial hypercholesterolemia (homozygous and heterozygous). For homozygous familial hypercholesterolemia, APO-ATORVASTATIN should be used as an adjunct to treatments such as LDL apheresis, or as monotherapy if such treatments are not available.</li><li>An adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia, if after an adequate trial of diet therapy the following findings are still present:<ul><li>LDL-C remains &gt;4.9 mmol/L (190 mg/dL) or</li><li>L-C remains &gt;4.1 mmol/L (160 mg/dL) and:<ul><li>there is a positive family history of premature cardiovascular disease or</li><li>two or more other CVD risk factors are present in the pediatric patient</li></ul></li></ul></li></ul><p>&nbsp;</p><p>Prior to initiating therapy with APO-ATORVASTATIN, secondary causes should be excluded for elevations in plasma lipid levels (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, and alcoholism), and a lipid profile performed to measure total cholesterol, LDL-C, HDL-C, and TG. For patients with TG &lt;4.52 mmol/L (&lt;400 mg/dL), LDL-C can be estimated using the following equation:</p><p>LDL-C (mmol/L) = total - C - [(0.37 x (TG) + HDL-C)]</p><p>LDL-C (mg/dL) = total - C - [(0.2 x (TG) + HDL-C)]</p><p>For patients with TG levels &gt;4.52 mmol/L (&gt;400 mg/dL), this equation is less accurate and LDL-C concentrations should be measured directly or by ultracentrifugation.</p><p>Patients with high or very high triglyceride levels, i.e. &gt;2.2 mmol/L (200 mg/dL) or &gt;5.6 mmol/L (500 mg/dL), respectively, may require triglyceride-lowering therapy (fenofibrate, bezafibrate or nicotinic acid) alone or in combination with APO-ATORVASTATIN.</p><p><strong>In general, combination therapy with fibrates must be undertaken cautiously and only after risk- benefit analysis </strong>(see WARNINGS AND PRECAUTIONS, Muscle Effects, Pharmacokinetic Interactions and INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).</p><p>Elevated serum triglycerides are most often observed in patients with the metabolic syndrome (abdominal obesity, atherogenic dyslipidemia {elevated triglycerides, small dense LDL particles and low HDL- cholesterol}, insulin resistance with or without glucose intolerance, raised blood pressure and prothrombic and proinflammatory states).</p><p>When drugs are prescribed attention to therapeutic lifestyle changes (reduced intake of saturated fats and cholesterol, weight reduction, increased physical activity, ingestion of soluble fibers) should always be maintained and reinforced.</p><p>&nbsp;</p><p><strong>Prevention of Cardiovascular Disease</strong></p><p>APO-ATORVASTATIN is indicated to reduce the risk of myocardial infarction in adult hypertensive patients without clinically evident coronary heart disease, but with at least three additional risk factors for coronary heart disease such as age &gt;55 years, male sex, smoking, type 2 diabetes, left ventricular hypertrophy, other specified abnormalities on ECG, microalbuminuria or proteinuria, ratio of plasma total cholesterol to HDL-cholesterol &gt;6, or premature family history of coronary heart disease.</p><p>APO-ATORVASTATIN is also indicated to reduce the risk of myocardial infarction and stroke in adult patients with type 2 diabetes mellitus and hypertension without clinically evident coronary heart disease, but with other risk factors such as age &ge;55 years, retinopathy, albuminuria or smoking.</p><p>APO-ATORVASTATIN is indicated to reduce the risk of myocardial infarction in patients with clinically evident coronary heart disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be placed on a standard cholesterol-lowering diet before receiving APO- ATORVASTATIN, and should continue on this diet during treatment with APO-ATORVASTATIN. If appropriate, a program of weight control and physical exercise should be implemented.</p><p>Prior to initiating therapy with APO-ATORVASTATIN, secondary causes for elevations in plasma lipid levels should be excluded. A lipid profile should also be performed.</p><p>&nbsp;</p><p><u>Primary Hypercholesterolemia and Combined (Mixed) Dyslipidemia, Including Familial Combined</u> <u>Hyperlipidemia</u></p><p>The recommended starting dose of APO-ATORVASTATIN is 10 or 20 mg once daily, depending on patient&rsquo;s LDL-C reduction required. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of APO-ATORVASTATIN is 10 to 80 mg once daily. Doses can be given at any time of the day with or without food, and should preferably be given in the evening. A significant therapeutic response is evident within 2 weeks, and the maximum response is usually achieved within 2-4 weeks. The response is maintained during chronic therapy. Adjustments of dosage, if necessary, should be made at intervals of 2 to 4 weeks. The maximum dose is 80 mg/day.</p><p>The dosage of APO-ATORVASTATIN should be individualized according the baseline LDL-C, total- C/HDL-C ratio and/or TG levels to achieve the recommended desired lipid values at the lowest dose needed to achieve LDL-C desired level. Lipid levels should be monitored periodically and, if necessary, the dose of APO-ATORVASTATIN adjusted based on desired lipid levels recommended by guidelines.</p><p>&nbsp;</p><p><u>Severe Dyslipidemias</u></p><p>In patients with severe dyslipidemias, including homozygous and heterozygous familial hypercholesterolemia and dysbetalipoproteinemia (Type III), higher dosages (up to 80 mg/day) may be required (see WARNINGS AND PRECAUTIONS, Pharmacokinetic Interactions, Muscle Effects; INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).</p><p>&nbsp;</p><p><strong>Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age)</strong></p><p>In this population, the recommended starting dose of APO-ATORVASTATIN is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg/day have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy (see THERAPEUTIC INDICATIONS and PHARMACOLOGY, Clinical Studies). Adjustments should be made at intervals of 4 weeks or more.</p><p>&nbsp;</p><p><strong>Prevention of Cardiovascular Disease</strong></p><p>Clinical trials conducted that evaluated atorvastatin in the primary prevention of myocardial infarction used a dose of 10 mg atorvastatin once daily.</p><p>For secondary prevention of myocardial infarction, optimal dosing may range from 10 mg to 80 mg atorvastatin once daily, to be given at the discretion of the prescriber, taking into account the expected benefit and safety considerations relevant to the patient to be treated.</p><p>&nbsp;</p><p><strong>Concomitant Therapy</strong></p><p>See INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION.</p><p>&nbsp;</p><p><strong>Dosage in Patients with Renal Insufficiency</strong></p><p>(See WARNINGS AND PRECAUTIONS)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to any component of this medication (for a complete listing of the components, see THERAPEUTIC INDICATIONS).

Active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal (see WARNINGS AND PRECAUTIONS).

Pregnancy and nursing women: Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). APO- ATORVASTATIN should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the possible harm. (If the patient becomes pregnant while taking APO-ATORVASTATIN, the drug should be discontinued immediately and the patient apprised of the potential harm to the fetus. Atherosclerosis being a chronic process, discontinuation of lipid metabolism regulating drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia (see PRECAUTIONS - Use in Pregnancy, Use in Nursing Mothers).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>General</u></strong></p><p>Before instituting therapy with APO-ATORVASTATIN (atorvastatin calcium), an attempt should be made to control elevated serum lipoprotein levels with appropriate diet, exercise, and weight reduction in overweight patients, and to treat other underlying medical problems (see THERAPEUTIC INDICATIONS). Patients should be advised to inform subsequent physicians of the prior use of APO- ATORVASTATIN or any other lipid-lowering agents.</p><p>&nbsp;</p><p><u>Pharmacokinetic Interactions</u></p><p>The use of HMG-CoA reductase inhibitors has been associated with severe myopathy, including rhabdomyolysis, which may be more frequent when they are co-administered with drugs that inhibit the cytochrome P-450 enzyme system. Atorvastatin is metabolized by cytochrome P-450 isoform 3A4 and as such may interact with agents that inhibit this enzyme. (See WARNINGS AND PRECAUTIONS, Muscle effects, and INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).</p><p>&nbsp;</p><p><u>Muscle Effects</u></p><p>Effects on skeletal muscle such as myalgia, myopathy and rarely, rhabdomyolysis have been reported in patients treated with atorvastatin.</p><p><strong>Rare cases of rhabdomyolysis, with acute renal failure secondary to myoglobinuria, have been reported with atorvastatin and with other HMG-CoA reductase inhibitors.</strong></p><p>Myopathy, defined as muscle pain or muscle weakness in conjunction with increases in creatine kinase (CK) values to greater than ten times the upper limit of normal, should be considered in any patient with diffuse myalgia, muscle tenderness or weakness, and/or marked elevation of CK. Patients should be advised to report promptly any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. Patients who develop any signs or symptoms suggestive of myopathy should have their CK levels measured. APO-ATORVASTATIN therapy should be discontinued if markedly elevated CK levels are measured or myopathy is diagnosed or suspected.</p><p><strong>Pre-disposing</strong><strong> </strong><strong>Factors</strong><strong> </strong><strong>for Myopathy/Rhabdomyolysis: </strong>APO-ATORVASTATIN, as with other HMG- CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><ul><li>Personal or family history of hereditary muscular disorders</li><li>Previous history of muscle toxicity with another HMG-CoA reductase inhibitor</li><li>Concomitant use of a fibrate, or niacin</li><li>Hypothyroidism</li><li>Alcohol abuse</li><li>Excessive physical exercise</li><li>Age &gt; 65 years</li><li>Renal impairment</li><li>Hepatic impairment</li><li>Diabetes with hepatic fatty change</li><li>Surgery and trauma</li><li>Frailty</li><li>Situations where an increase in plasma levels of active ingredient may occur</li></ul><p>The risk of myopathy and rhabdomyolysis during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of drugs that interfere with metabolism of atorvastatin via CYP 3A4, such as cyclosporin, fibric acid derivatives, erythromycin, clarithromycin, niacin (nicotinic acid), azole antifungals, nefazodone, colchicine, the hepatitis C protease inhibitor telaprevir, boceprevir, HIV protease inhibitor fosamprenavil and each of the following HIV protease inhibitor combinations: saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir and fosamprenavil plus ritonavir. The combined therapy with APO-ATORVASTATIN and cyclosporine, gemfibrozil, telaprevir or tipranavir plus ritonavir should be avoided. APO-ATORVASTATIN dose restriction or caution is recommended for combined therapy with other CYP 3A4 inhibitors (see Pharmacokinetic Interactions; INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION, Drug-Drug Interactions; DETAILED PHARMACOLOGY, Human Pharmacokinetics).</p><p>In cases where co-administration of APO-ATORVASTATIN with cyclosporine is necessary, the dose of atorvastatin should not exceed 10 mg. Temporary suspension of atorvastatin during fusidic acid therapy is recommended (see INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION, Drug-Drug Interactions).</p><p>Although patients with renal impairment are known to be predisposed to the development of rhabdomyolysis with administration of HMG-CoA reductase inhibitors (also known as statins), those with a history of renal impairment may also be predisposed to the development of rhabdomyolysis. Such patients merit close monitoring for skeletal muscle effects.</p><p>APO-ATORVASTATIN therapy should be temporarily withheld or discontinued in any patient with an acute serious condition suggestive of myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (such as sepsis, severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures).</p><p><strong>APO-ATORVASTATIN therapy</strong><strong> should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Cardiovascular</u></strong></p><p><u>Hemorrhagic Stroke in Patients with Recent Stroke or Transient Ischemic Attack (TIA)</u></p><p>A post-hoc analysis of a clinical study in 4,731 patients without coronary heart disease (CHD) who had a stroke or TIA within the preceding six months revealed a higher incidence of hemorrhagic stroke in the atorvastatin 80 mg group compared to placebo. Patients with hemorrhagic stroke on entry appeared to be at increased risk for recurrent hemorrhagic stroke. The potential risk of hemorrhagic stroke should be carefully considered before initiating treatment with atorvastatin in patients with recent (1-6 months) stroke or TIA.</p><p>&nbsp;</p><p><u>Effect on Ubiquinone (CoQ10)Levels</u></p><p>Significant decreases in circulating ubiquinone levels in patients treated with atorvastatin and other statins have been observed. The clinical significance of a potential long-term statin-induced deficiency of ubiquinone has not been established. It has been reported that a decrease in myocardial ubiquinone levels could lead to impaired cardiac function in patients with borderline congestive heart failure (see REFERENCES).</p><p>&nbsp;</p><p><strong><u>Endocrine and Metabolism</u></strong></p><p><u>Endocrine Function</u></p><p>HMG-CoA reductase inhibitors interfere with cholesterol synthesis and as such might theoretically blunt adrenal and/or gonadal steroid production. Clinical studies with atorvastatin and other HMG-CoA reductase inhibitors have suggested that these agents do not reduce plasma cortisol concentration or impair adrenal reserve and do not reduce basal plasma testosterone concentration. However, the effects of HMG-CoA reductase inhibitors on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown.</p><p>Patients treated with atorvastatin who develop clinical evidence of endocrine dysfunction should be evaluated appropriately. Caution should be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients receiving other drugs (e.g. ketoconazole, spironolactone or cimetidine) that may decrease the levels of endogenous steroid hormones.</p><p>Increases in fasting glucose and HbA1c levels have been reported with inhibitors of HMG-CoA reductase as a class. For some patients, at high risk of diabetes mellitus, hyperglycemia was sufficient to shift them to the diabetes status. The benefit of treatment continues to outweigh the small increased risk. Periodic monitoring of these patients is recommended.</p><p>&nbsp;</p><p><u>Effect on Lipoprotein (a</u>)</p><p>In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by a concomitant increase in Lp(a) lipoprotein concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease. It is thus desirable to maintain and reinforce lifestyle changes in high risk patients placed on atorvastatin therapy (see REFERENCES).</p><p>&nbsp;</p><p><u>Patients with Severe Hypercholesterolemia</u></p><p>Higher drug dosages (80 mg/day) required for some patients with severe hypercholesterolemia (including familial hypercholesterolemia) are associated with increased plasma levels of atorvastatin. <strong>Caution should be exercised in such patients who are also severely renally impaired, elderly, or are concomitantly being administered digoxin or CYP 3A4 inhibitors </strong>(see WARNINGS AND PRECAUTIONS, Pharmacokinetic Interactions, Muscle Effects; INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION; DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p><strong><u>Hepatic/Biliary/Pancreatic</u></strong></p><p><u>Hepatic Effects</u></p><p>In clinical trials, persistent increases in serum transaminases greater than three times the upper limit of normal occurred in &lt;1% of patients who received atorvastatin. When the dosage of atorvastatin was reduced, or when drug treatment was interrupted or discontinued, serum transaminase levels returned to pretreatment levels. The increases were generally not associated with jaundice or other clinical signs or symptoms. Most patients continued treatment with a reduced dose of atorvastatin without clinical sequelae. <strong>If increases in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) show evidence of progression, particularly if they rise to greater than 3 times the upper limit of normal and are persistent, the dosage should be reduced or the drug discontinued.</strong></p><p>Liver function tests should be performed before the initiation of treatment, and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with APO-ATORVASTATIN,&nbsp; promptly interrupt therapy. If an alternate etiology is not found, do not restart APO-ATORVASTATIN.</p><p><strong>APO-ATORVASTATIN,</strong><strong> as well as other HMG-CoA reductase inhibitors, should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. </strong>Active liver disease or unexplained transaminase elevations are contraindications to the use of atorvastatin; if such a condition should develop during therapy, the drug should be discontinued.</p><p>&nbsp;</p><p><strong><u>Ophthalmologic</u></strong></p><p><u>Effect on the Lens</u></p><p>Current long-term data from clinical trials do not indicate an adverse effect of atorvastatin on the human lens.</p><p>&nbsp;</p><p><strong><u>Renal</u></strong></p><p><u>Renal Insufficiency</u></p><p>Plasma concentrations and LDL-C lowering efficacy of atorvastatin was shown to be similar in patients with moderate renal insufficiency compared with patients with normal renal function. However, since several cases of rhabdomyolysis have been reported in patients with a history of renal insufficiency of unknown severity, as a precautionary measure and pending further experience in renal disease, the lowest dose (10 mg/day) of APO-ATORVASTATIN should be used in these patients. Similar precautions apply in patients with severe renal insufficiency [creatinine clearance &lt;30 mL/min (&lt;0.5 mL/sec)]; the lowest dosage should be used and implemented cautiously (see WARNINGS AND PRECAUTIONS, Muscle Effects; INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION). Refer also to DOSAGE AND ADMINISTRATION.</p><p>&nbsp;</p><p><strong><u>Sensitivity/Resistance</u></strong></p><p><u>Hypersensitivity</u></p><p>An apparent hypersensitivity syndrome has been reported with other HMG-CoA reductase inhibitors which has included 1 or more of the following features: anaphylaxis, angioedema, lupus erythematous- like syndrome, polymyalgia rheumatica, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome. Although to date hypersensitivity syndrome has not been described as such, APO-ATORVASTATIN should be discontinued if hypersensitivity is suspected.</p><p>&nbsp;</p><p><strong><u>Special Populations</u></strong></p><p><strong>Pediatric Use: </strong>Safety and effectiveness of atorvastatin in patients 10-17 years of age (N=140) with heterozygous familial hypercholesterolemia have been evaluated in a controlled clinical trial of 6 months duration in adolescent boys and postmenarchal girls. Patients treated with atorvastatin had a safety and tolerability profile generally similar to that of placebo. Doses greater than 20 mg have not been studied in this patient population.</p><p>Safety and effectiveness of atorvastatin in pediatric patients has not been determined in the prevention of myocardial infarction.</p><p>Atorvastatin had no effect on growth or sexual maturation in boys and in girls. The effects on menstrual cycle were not assessed [see PHARMACOLOGY, Clinical Studies section; UNDESIRABLE EFFECTS, Pediatric Patients; and DOSAGE AND ADMINISTRATION for Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age)].</p><p>Adolescent females should be counselled on appropriate contraceptive methods while on</p><p>APO-ATORVASTATIN therapy (see CONTRAINDICATIONS and PRECAUTIONS, Use in</p><p>Pregnancy). Atorvastatin has not been studied in controlled clinical trials involving pre-pubertal patients or patients younger than 10 years of age.</p><p>Doses of atorvastatin up to 80 mg/day for 1 year have been evaluated in 8 pediatric patients with homozygous familial hypercholesterolemia (see Clinical Studies - Heterozygous Familial Hypercholesterolemia in pediatric patients).</p><p>&nbsp;</p><p><strong>Geriatric Use: </strong>Treatment experience in adults 70 years or older (N=221) with doses of atorvastatin up to 80 mg/day has demonstrated that the safety and effectiveness of atorvastatin in this population was similar to that of patients &lt;70 years of age. Pharmacokinetic evaluation of atorvastatin in subjects over the ag&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; e of 65 years indicates an increased AUC. As a precautionary measure, the lowest dose should be administered initially (see DETAILED PHARMACOLOGY, Human Pharmacokinetics; REFERENCES).</p><p>Elderly patients may be more susceptible to myopathy (see WARNINGS - Muscle Effects - Predisposing Factors for Myopathy/Rhabdomyolysis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic interaction studies conducted with drugs in healthy subjects may not detect the possibility of a potential drug interaction in some patients due to differences in underlying diseases and use of concomitant medications (see also WARNINGS AND PRECAUTIONS, Special Populations; Renal Insufficiency; Patients with Severe Hypercholesterolemia; Geriatric Use).</p><p>&nbsp;</p><p><strong>Concomitant Therapy with Other Lipid Metabolism Regulators: </strong>Based on post-marketing surveillance, gemfibrozil, fenofibrate, other fibrates, and lipid-modifying doses of niacin (nicotinic acid) may increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone (see WARNINGS -Muscle Effects). The concomitant use of APO-ATORVASTATIN with gemfibrozil should be avoided. The combined therapy with other fibrates and niacin should be used with caution; lower starting and maintenance doses of atorvastatin should be considered.</p><p>&nbsp;</p><p><strong>Cytochrome P-450-mediated Interactions: </strong>Atorvastatin is metabolized by the cytochrome P-450 isoenzyme, CYP 3A4. Erythromycin, a CYP 3A4 inhibitor, increased atorvastatin plasma levels by 40%. Coadministration of CYP 3A4 inhibitors, such as grapefruit juice, some macrolide antibiotics (i.e. erythromycin, clarithromycin), immunosuppressants (cyclosporine), azole antifungal agents (i.e. itraconazole, ketoconazole), protease inhibitors, or the antidepressant, nefazodone, have the potential to increase plasma concentrations of HMG CoA reductase inhibitors, including atorvastatin (see Drug-Drug Interactions, REFERENCES).&nbsp; Concomitant use of APO-ATORVASTATIN with cyclosporine, gemfibrozil, telaprevir or the combination of tipranavir with ritonavir should be avoided. Other CYP 3A4 inhibitors should be used with APO-ATORVASTATIN dose restriction or caution, and patients should be monitored closely for musculoskeletal effects (see WARNINGS AND PRECAUTIONS, Pharmacokinetic Interactions, Muscle Effects, Renal Insufficiency and Endocrine Function; Drug-Drug Interactions, Table 2 &ndash; Established or Potential Drug-Drug Interactions; REFERENCES).</p><p>Pharmacokinetic drug interactions that result in increased systemic concentration of atorvastatin have been noted with HIV protease inhibitors (lopinavir plus ritonavir, saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir and nelfinavir), Hepatitis C protease inhibitor (boceprevir), clarithromycin and itraconazole. Caution should be used when co-prescribing atorvastatin and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin is employed (see Drug-Drug Interactions, Table 2 - Established or Potential Drug-Drug Interactions).</p><p>&nbsp;</p><p><strong>Transporter Inhibitors</strong>: Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g. cyclosporine) can increase the bioavailability of atorvastatin (see DETAILED PHARMACOLOGY, Human Pharmacokinetics).</p><p>&nbsp;</p><p><strong>Inducers of cytochrome P450 3A: </strong>Concomitant administration of atorvastatin with inducers of cytochrome P450 3A4 (eg efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, (cytochrome P450 3A4 induction and inhibition of hepatocyte uptake transporter OATP1B1), simultaneous co-administration of atorvastatin with rifampin resulted in a mean increase in Cmax&nbsp;and AUC of atorvastatin of 12 and 190%, respectively. In contrast, a delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction (approximately 80%) in atorvastatin plasma concentrations.</p><p>&nbsp;</p><p><strong><u>Drug-Drug Interactions</u></strong></p><p>The drugs listed in this table are based on either drug interactions studies, case reports, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated). Interactions with other drugs have not been established.</p><p>&nbsp;</p><p><strong>Table 2: Established or Potential Drug -Drug Interactions</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Proper name</strong></p></td><td><p><strong>Effect</strong></p></td><td><p><strong>Clinical</strong><strong> </strong><strong>comment</strong></p></td></tr><tr><td><p>Bile Acid Sequestrants</p></td><td><p><u>Patients</u><u> </u><u>with</u><u> </u><u>mild</u><u> </u><u>to moderate</u><u> </u><u>HC</u>: &uarr; LDL-C reduction (-45%) when atorvastatin 10 mg and colestipol 20 g were coadministered than when either drug was administered alone (-35% for atorvastatin and -22% for colestipol).</p><p><strong>&nbsp;</strong></p><p><u>Patients</u><u> </u><u>with</u><u> </u><u>severe</u><u> </u><u>HC</u>: LDL-C reduction was similar (-53%) when atorvastatin 40 mg and colestipol 20 g were coadministered when compared to that with atorvastatin 80 mg alone. &darr; plasma concentration (~26%) when atorvastatin 40 mg plus colestipol 20 g were co-administered compared with atorvastatin 40 mg alone.</p><p>However, the combination drug therapy was less effective in lowering TG than atorvastatin monotherapy in both types of hypercholesterolemic patients.</p></td><td><p>When atorvastatin is used concurrently with colestipol or any other resin, an interval of at least 2 hours should be maintained between the two drugs, since the absorption of atorvastatin may be impaired by the resin.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Proper name</strong></p></td><td><p><strong>Effect</strong></p></td><td><p><strong>Clinical</strong><strong> </strong><strong>comment</strong></p></td></tr><tr><td><p>Fibric Acid Derivatives (Gemfibrozil, Fenofibrate, Bezafibrate) and Niacin (nicotinic acid)</p></td><td><p>&uarr; in the risk of myopathy during treatment with other drugs in this class, including atorvastatin, with concurrent administration with a fibric acid derivative</p></td><td><p>The concomitant therapy with APO-ATORVASTATIN and gemfibrozil should be avoided. The benefits and risks of combined therapy with APO-ATORVASTATIN and fenofibrate, bezafibrate and niacin should be carefully considered (see WARNINGS AND PRECAUTIONS, Muscle Effects and REFERENCES).</p></td></tr><tr><td><p>Coumarin Anticoagulants</p></td><td><p>No clinically significant effect on prothrombin time</p></td><td><p>Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin therapy (see REFERENCES).</p></td></tr><tr><td><p>Digoxin</p></td><td><p>In healthy subjects, digoxin PK at steady-state were not significantly altered by coadministration of digoxin 0.25 mg and atorvastatin 10 mg daily.</p><p>&nbsp;</p><p><strong>&uarr; </strong>in digoxin steady-state concentrations by ~20% following coadministration of digoxin 0.25 mg and atorvastatin 80 mg daily (see DETAILED PHARMACOLOGY, Human Pharmacokinetics).</p></td><td><p>Patients taking digoxin should be monitored appropriately.</p></td></tr><tr><td><p><u>Antihypertensive</u><u> </u><u>Agents</u>: Amlodipine</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Quinapril</p></td><td><p>In healthy subjects, atorvastatin PK were not altered by the coadministration of atorvastatin 80 mg and amlodipine 10 mg at steady state. No apparent changes in BP or HR.</p><p>Steady-state quinapril dosing of 80 mg QD did not significantly affect the PK profile of atorvastatin tablets 10 mg QD.</p></td><td><p>See DETAILED PHARMACOLOGY - Human Pharmacokinetics</p></td></tr><tr><td><p>Oral Contraceptives and Hormone Replacement Therapy</p></td><td><p><strong>&uarr; </strong>plasma concentrations (AUC levels) of norethindone by <em>~</em>30% and ethinyl estradiol by ~20% following coadministration of atorvastatin with an oral contraceptive containing 1 mg norethindone and 35 &mu;g ethinyl estradiol.</p><p>In clinical studies, atorvastatin was used concomitantly with estrogen replacement therapy without evidence to date of clinically significant adverse interactions.</p></td><td><p>These increases should be considered when selecting an oral contraceptive.</p></td></tr><tr><td><p>Antacids</p></td><td><p>&darr; in plasma concentrations of atorvastatin by ~35% following administration of aluminum and magnesium based antacids, such as Maalox&reg; TC Suspension.</p><p>LDL-C reduction was not altered; TG-lowering effect of atorvastatin may be affected.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Proper name</strong></p></td><td><p><strong>Effect</strong></p></td><td><p><strong>Clinical</strong><strong> </strong><strong>comment</strong></p></td></tr><tr><td><p>Cimetidine</p></td><td><p>No effect on plasma concentrations or LDL-C lowering efficacy of atorvastatin &darr; in TG-lowering effect of atorvastatin from 34% to 26%</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Diltiazem Hydrochloride</p></td><td><p>Steady-state diltiazem increases the exposure, based on AUCLASTs, of a single dose of atorvastatin by approximately 50%.</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Antipyrine</p></td><td><p>Atorvastatin had no effect on the PK of antipyrine.</p></td><td><p>Antipyrine was used as a non-specific model for drugs metabolized by the microsomal hepatic enzyme system (cytochrome P-450 system).</p><p>Interactions with other drugs metabolized via the same cytochrome isozymes are not expected.</p></td></tr><tr><td><p>Macrolide Antibiotics (azithromycin, clarithromycin, erythromycin).</p><p>Clarithromycin and erythromycin are both CYP3A4 inhibitors</p></td><td><p>In healthy adults, coadministration of atorvastatin (10mg QD) and azithromycin (500 mg QD) did not significantly alter the plasma concentrations of atorvastatin.</p><p>&uarr; plasma concentration by ~40% with erythromycin (500 mg QID) and ~80% with clarithromycin (500 mg BID) when coadministered with atorvastatin (10 mg QD)</p></td><td><p>See WARNINGS AND PRECAUTIONS, Muscle Effects; DETAILED PHARMACOLOGY - Human Pharmacokinetics</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Proper name</strong></p></td><td><p><strong>Effect</strong></p></td><td><p><strong>Clinical</strong><strong> </strong><strong>comment</strong></p></td></tr><tr><td><p>Protease Inhibitors</p></td><td><p>&uarr; plasma concentrations of atorvastatin when atorvastatin 10 mg QD is coadministered with nelfinavir mesylate 1250 mg BID. &uarr; AUC by 74% and &uarr; Cmax&nbsp;by 122%</p><p>&uarr; AUC by 5.9 fold and &uarr; Cmax&nbsp;by 4.7 fold with atorvastatin 20mg QD and Lopinavir 400mg / Ritonavir 100mg BID*</p><p>&uarr; AUC by 8.4 fold and &uarr;Cmax by 7.6 fold with atorvastatin 10mg SD and Tipranavir 500mg BID / Ritonavir 200mg BID, 7 days. Atorvastatin 10 mg SD had no effect on the PK of Tripanavir 500mg BID / Ritonavir 200 mg BID, 7 days*</p><p>&uarr; AUC by 6.9 fold and &uarr;Cmax by 9.6 fold with atorvastatin 20mg SD and Telaprevir 750mg q8h, 10 days*</p><p>&uarr; AUC by 2.9 fold and &uarr;Cmax by 3.3 fold with atorvastatin 40mg QD for 4 days and Ritonavir 400mg BID, 15 days / Saquinavir 400mg BID*&dagger;</p><p>&uarr;AUC by 2.4 fold and &uarr;Cmax by 1.3 fold with atorvastatin 10mg QD for 4 days and Darunavir 300mg BID/ Ritonavir 100 mg BID, 9 days*</p><p>&uarr; AUC by 1.5 fold and &uarr;Cmax by 1.8 fold with atorvastatin 10mg QD for 4 days and Fosamprenavir 700 mg BID/ritonavir 100mg BID,14 days*</p><p>&uarr; AUC by 1.3 fold and &uarr;Cmax by 3.0 fold with atorvastatin 10mg QD for 4 days and Fosamprenavir 1400 mg BID, 14 days*. Atorvastatin 10mg QD for 4 days had the following effect on the PK of Fosamprenavir 1400 mg BID, 14 days: &darr; AUC by 0.27 fold and &uarr;Cmax by 0.18 fold*</p><p>Atorvastatin 10mg QD, 4 days had no effect on the PK of Fosamprenavir 700mg BID/ Ritonavir 100 mg BID, 14 days*</p></td><td><p>The dose of APO-ATORVASTATIN used in combination with nelfinavir should not exceed 40 mg daily.</p><p>The concomitant therapy with APO-ATORVASTATIN and the combination of lopinavir plus ritonavir should be used with caution and lowest LIPITOR dose necessary. (See Warnings and Precautions, Muscle Effect)</p><p>The concomitant therapy with APO-ATORVASTATIN and the combination of tipranavir plus ritonavir or APO-ATORVASTATIN and telaprevir should be avoided.</p><p>The dose of APO-ATORVASTATIN used in combination with saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir alone or fosamprenavir plus ritonavir should be restricted to 20 mg daily.</p><p>&dagger; The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study.</p><p>Therefore caution should be applied and the lowest dose necessary should be used</p></td></tr><tr><td><p>Cyclosporine</p></td><td><p>Concomitant administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day resulted in a 7.7 fold increase in exposure to atorvastatin.</p></td><td><p>Concomitant use should be avoided. See WARNINGS and PRECAUTIONS - Muscle Effects; DETAILED PHARMACOLOGY &ndash; Human Pharmacokinetics See WARNINGS and PRECAUTIONS - Muscle Effects; DETAILED PHARMACOLOGY &ndash; Human Pharmacokinetics</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Proper name</strong></p></td><td><p><strong>Effect</strong></p></td><td><p><strong>Clinical</strong><strong> </strong><strong>comment</strong></p></td></tr><tr><td><p>Itraconazole</p></td><td><p>Concomitant administration of atorvastatin 20- 40mg and itraconazole 200mg daily resulted in a 2.5-3.3-fold increase in atorvastatin AUC.</p></td><td><p>The dose of LIPITOR used in combination with itraconazole should not exceed 20 mg daily (see DETAILED PHARMACOLOGY &ndash; Human Pharmacokinetics).</p></td></tr><tr><td><p>Efavirenz</p></td><td><p>&darr; AUC by 41 %and &darr; Cmax by 1% with atorvastatin 10mg and Efavirenz 600mg daily.</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rifampin</p></td><td><p><u>Co-administration*:</u></p><p>&uarr; AUC by 30% and &uarr; Cmax by 2.7 fold co-administered atorvastatin 40mg single dose and Rifampin 600mg daily</p><p><u>Separate</u><u> </u><u>administration*</u></p><p>&darr; in AUC by 80% and &darr; Cmax by 40% with atorvastatin 40mg single dose and Rifampin 600mg daily (doses separated )</p></td><td><p>Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations</p></td></tr><tr><td><p>Fusidic Acid</p></td><td><p>Although interaction studies with atorvastatin and fusidic acid have not been conducted, severe muscle problems such as rhabdomyolysis have been reported in post- marketing experience with this combination.</p></td><td><p>Temporary suspension of atorvastatin treatment should be considered (see WARNINGS AND PRECAUTIONS &ndash; Muscle Effects)<em>.</em></p></td></tr><tr><td><p>Colchicine</p></td><td><p>Although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administrated with colchicine.</p></td><td><p>Caution should be exercised when prescribing atorvastatin with colchicine. (See Warnings and Precautions, Muscle Effect)</p></td></tr></tbody></table><p>Legend:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HC = hypercholesterolemia; TG = triglycerides; PK = pharmacokinetics; BP <em>= </em>Blood Pressure; HR = Heart Rate; AUC = Area under the curve</p><p>* Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).</p><p>&nbsp;</p><p><strong><u>Drug-Food Interactions</u></strong></p><p>Coadministration of grapefruit juice has the potential to increase plasma concentrations of HMG-CoA reductase inhibitors, including atorvastatin. The equivalent of 1.2 litres per day resulted in a 2.5 fold increase in AUC of atorvastatin. Consumption of excessive grapefruit juice with atorvastatin is not recommended.</p><p>&nbsp;</p><p><strong><u>Drug-Herb Interactions</u>&nbsp;</strong></p><p>Interactions with herbal products have not been established.</p><p>&nbsp;</p><p><strong><u>Drug/Laboratory Test Interactions</u></strong></p><p>APO-ATORVASTATIN may elevate serum transaminase and creatine kinase levels (from skeletal muscle). In the differential diagnosis of chest pain in a patient on therapy with APO-ATORVASTATIN, cardiac and noncardiac fractions of these enzymes should be determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use in Pregnancy: </u>(pregnancy category X)</p><p>APO-ATORVASTATIN is contraindicated during pregnancy (see CONTRAINDICATIONS). There are no data on the use of atorvastatin during pregnancy. APO-ATORVASTATIN should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking APO-ATORVASTATIN, the drug should be discontinued and the patient apprised of the potential risk to the fetus.</p><p>&nbsp;</p><p><u>Use in Nursing Mothers<strong>:</strong></u></p><p>In rats, milk concentrations of atorvastatin are similar to those in plasma. It is not known whether this drug is excreted in human milk. Because of the potential for Undesirable effects in nursing infants, women taking APO-ATORVASTATIN should not breast-feed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No or negligible influence.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects with atorvastatin have usually been mild and transient. In the atorvastatin placebo- controlled clinical trial database of 16,066 (8755 Lipitor versus 7311 placebo) patients treated for a median period of 53 weeks , 5.2% of patients on atorvastatin discontinued due to Undesirable effects compared to 4.0% of the patients on placebo.</p><p>Adverse experiences occurring at an incidence &ge;1% in patients participating in placebo-controlled clinical studies of atorvastatin and reported to be possibly, probably or definitely drug related are shown in Table 1 below:</p><p>&nbsp;</p><p><strong>Table 1: Associated Adverse Events Reported in &ge;1 % of Patients in Placebo Controlled Clinical Trials</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Atorvastatin</strong><strong> </strong><strong>%</strong></p><p><strong>(n=8755)</strong></p></td><td><p><strong>Placebo</strong><strong> </strong><strong>%</strong></p><p><strong>(n=7311)</strong></p></td></tr><tr><td><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders:</strong></p></td><td rowspan="2"><p>&nbsp;</p><p>6.8</p></td><td rowspan="2"><p>&nbsp;</p><p>6.3</p></td></tr><tr><td><p>Diarrhea</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>4.6</p></td><td><p>4.3</p></td></tr><tr><td><p>Nausea</p></td><td><p>4.0</p></td><td><p>3.5</p></td></tr><tr><td><p>Constipation</p></td><td><p>3.9</p></td><td><p>4.3</p></td></tr><tr><td><p>Flatulence</p></td><td><p>1.2</p></td><td><p>1.0</p></td></tr><tr><td><p><strong>General</strong><strong> </strong><strong>disorders and administration site conditions:</strong></p><p>Asthenia</p></td><td><p>&nbsp;</p><p>1.1</p></td><td><p>&nbsp;</p><p>1.1</p></td></tr><tr><td><p><strong>Infections</strong><strong> </strong><strong>and Infestations:</strong></p><p>Nasopharyngitis</p></td><td><p>&nbsp;</p><p>8.3</p></td><td><p>&nbsp;</p><p>8.2</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders:</strong></p></td><td rowspan="2"><p>&nbsp;</p><p>4.1</p></td><td rowspan="2"><p>&nbsp;</p><p>2.0</p></td></tr><tr><td><p>Liver function test abnormal*</p></td></tr><tr><td><p>Blood creatine phosphokinase increased</p></td><td><p>1.9</p></td><td><p>1.8</p></td></tr><tr><td><p>Hyperglycemia</p></td><td><p>5.9</p></td><td><p>5.5</p></td></tr><tr><td><p><strong>Musculoskeletal</strong><strong> </strong><strong>and connective tissue disorders:</strong></p></td><td rowspan="2"><p>&nbsp;</p><p>6.9</p></td><td rowspan="2"><p>&nbsp;</p><p>6.5</p></td></tr><tr><td><p>Arthralgia</p></td></tr><tr><td><p>Pain in extremity</p></td><td><p>6.0</p></td><td><p>5.9</p></td></tr><tr><td><p>Musculoskeletal pain</p></td><td><p>3.8</p></td><td><p>3.6</p></td></tr><tr><td><p>Muscle spasms</p></td><td><p>3.6</p></td><td><p>3.0</p></td></tr><tr><td><p>Myalgia</p></td><td><p>3.5</p></td><td><p>3.1</p></td></tr><tr><td><p>Joint swelling</p></td><td><p>1.3</p></td><td><p>1.2</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p>6.5</p></td><td><p>6.7</p></td></tr><tr><td><p>Headache</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>Respiratory, thoracic and mediastinal disorders:</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Pharyngolaryngeal pain</p></td><td><p>2.3</p></td><td><p>2.1</p></td></tr><tr><td><p>Epistaxis</p></td><td><p>1.2</p></td><td><p>1.1</p></td></tr></tbody></table><p>*alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, hepatic enzyme increased, liver function test abnormal and transaminases increased.</p><p>The following additional adverse events were reported in placebo-controlled clinical trials during atorvastatin therapy: Muscle cramps, myositis, muscle fatigue, myopathy, paresthesia, peripheral neuropathy, pancreatitis, hepatitis, cholestatic jaundice, cholestasis, anorexia, vomiting, abdominal discomfort, alopecia, pruritus, rash, urticaria , erectile dysfunction, nightmare, vision blurred, tinnitus, eructation, neck pain, malaise, pyrexia and white blood cells urine positive.</p><p>&nbsp;</p><p>In summary, the adverse events occurring at a frequency &lt;1% are listed below:</p><p><strong>General disorders and administration site conditions: </strong>malaise; pyrexia</p><p><strong>Gastrointestinal disorders: </strong>abdominal discomfort, eructation</p><p><strong>Hepatobiliary</strong><strong> disorders: </strong>hepatitis, cholestasis</p><p><strong>Musculoskeletal</strong><strong> </strong><strong>and connective</strong><strong> </strong><strong>tissue</strong><strong> disorders: </strong>muscle fatigue, neck pain</p><p><strong>Psychiatric</strong><strong> disorders: </strong>nightmare</p><p><strong>Skin and subcutaneous tissue disorders: </strong>urticaria</p><p><strong>Eye</strong><strong> disorders: </strong>vision blurred</p><p><strong>Ear</strong><strong> and labyrinth disorders: </strong>tinnitus</p><p><strong>Investigations:</strong><strong> </strong>white blood cells urine positive</p><p>&nbsp;</p><p><strong><u>Heterozygous Familial Hypercholesterolemia in Pediatric Patients (ages 10-17 years)</u>:</strong></p><p>In a 26-week controlled study in boys and postmenarchal girls (n=187, where 140 patients received atorvastatin), the safety and tolerability profile of atorvastatin 10 to 20 mg daily was similar to that of placebo. The adverse events reported in &gt;1% of patients were as follows: abdominal pain, depression and headache (see PHARMACOLOGY, Clinical Studies and PRECAUTIONS, Pediatric Use).</p><p>&nbsp;</p><p><strong>Laboratory Changes and Adverse Events</strong></p><p>The criteria for clinically significant laboratory changes were &gt;3 X the upper limit of normal (ULN) for liver enzymes, and &gt;5 X ULN for creatine kinase. A total of 8 unique subjects met one or more of these criteria during the double-blind phase. Hence, the incidence of patients who experienced abnormally high enzymatic levels (AST/ALT and creatine kinase) was &gt;4% (8/187).</p><p>Five atorvastatin and one placebo subjects had increases in CK <em>&gt;</em>5 X ULN during the double-blind phase; two of the five atorvastatin treated subjects had increases in CK &gt;10 X ULN.</p><p>There were 2 subjects who had clinically significant increases in ALT.</p><p>&nbsp;</p><p><strong><u>Abnormal Hematologic and Clinical Chemistry Findings</u></strong></p><p>Laboratory Tests: Increases in serum transaminase levels and serum glucose have been noted in clinical trials (see WARNINGS AND PRECAUTIONS, UNDESIRABLE EFFECTS).</p><p>&nbsp;</p><p><strong><u>Post-Market Adverse Drug Reactions</u></strong></p><p>The following adverse events have also been reported during post-marketing experience with atorvastatin, regardless of causality assessment:</p><p>Rare reports: severe myopathy with or without rhabdomyolysis (see WARNINGS AND PRECAUTIONS, Muscle Effects, Renal Insufficiency and INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).</p><p>There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents.</p><p>Isolated reports: Gynecomastia, thrombocytopenia, arthralgia and allergic reactions including urticaria, angioneurotic edema, anaphylaxis and bullous rashes (including erytheme multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis), fatigue, back pain, chest pain, malaise, dizziness, amnesia, peripheral edema, weight gain, abdominal pain, insomnia, hypoesthesia, tinnitus, tendon rupture, pancreatitis and dysgeusia.</p><p>Ophthalmologic observations: see WARNINGS AND PRECAUTIONS.</p><p>Cases of erectile dysfunction have been reported in association with the use of statins. The following adverse events have been reported with some statins:</p><ul><li>Sleep disturbances, including insomnia and nightmares;</li><li>Mood related disorders, including depression;</li><li>Very rare cases of interstitial lung disease, especially with long term therapy. If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</li></ul><p>Endocrine disorders: Increases in fasting glucose and HbA1c levels have been reported with APO-ATORVASTATIN.</p><p>There have been rare post-marketing reports of cognitive impairment (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally non-serious and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).</p><p>&nbsp;</p><p>-&nbsp; To report any side effect(s)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for atorvastatin overdosage. Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance (see UNDESIRABLE EFFECTS)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The lowering of total cholesterol, LDL-C and ApoB have been shown to reduce the risk of cardiovascular events and mortality.</p><p>&nbsp;</p><p>Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. In both subjects and in patients with homozygous and heterozygous familial hypercholesterolemia, nonfamilial forms of hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia, and dysbetalipoproteinemia, atorvastatin has been shown to reduce levels of total cholesterol (total-C), LDL-C, apo B and total TG, and raises HDL-C levels.</p><p>&nbsp;</p><p>Epidemiologic and clinical studies have associated the risk of coronary artery disease (CAD) with elevated levels of total-C, LDL-C and decreased levels of HDL-C. These abnormalities of lipoprotein metabolism are considered as major contributors to the development of the disease. Like LDL, cholesterol-enriched lipoproteins, including VLDL, IDL and remnants can also promote atherosclerosis. Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease (metabolic syndrome). Clinical studies have also shown that serum triglycerides can be an independent risk factor for CAD. CAD risk is especially increased if the hypertriglyceridemia is due to increased intermediate density lipoproteins (IDL) or associated with decreased HDL or increased LDL-C. In addition, high TG levels are associated with an increased risk of pancreatitis. Although epidemiological and preliminary clinical evidence link low HDL-C levels and high triglyceride levels with coronary artery disease and atherosclerosis, the independent effect of raising HDL or lowering TG on the risk of coronary and cerebrovascular morbidity and mortality has not been demonstrated in prospective, well-controlled outcome studies. Other factors, e.g. interactions between lipids/lipoproteins and endothelium, platelets &nbsp;and macrophages, have also been incriminated in the development of human atherosclerosis and of its complications. Regardless of the intervention used (low-fat/low-cholesterol diet, partial ileal bypass surgery or pharmacologic therapy), effective treatment of hypercholesterolemia/ dyslipidemia has consistently been shown to reduce the risk of CAD.</p><p>Atorvastatin reduces LDL-C and the number of LDL particles, lowers Very Low Density Lipoprotein- Cholesterol (VLDL-C) and serum triglyceride, reduces the number of apo B containing particles, and also increases HDL-C. Atorvastatin is effective in reducing LDL-C in patients with homozygous familial hypercholesterolemia, a condition that rarely responds to any other lipid-lowering medication. In addition to the above effects, atorvastatin reduces IDL-C and apolipoprotein E (apo E) in patients with dysbetalipoproteinemia (Type III).</p><p>In patients with type II hyperlipidemia, atorvastatin improved endothelial dysfunction. Atorvastatin significantly improved flow-mediated endothelium-dependent dilatation induced by reactive hyperemia, as assessed by brachial ultrasound (p&lt;0.01).</p><p>&nbsp;</p><p><strong><u>Mechanism of Action</u></strong></p><p>Atorvastatin is a synthetic lipid-lowering agent. It is a selective, competitive inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol.</p><p>Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic Low Density Lipoprotein (LDL) receptors on the cell-surface for enhanced uptake and catabolism of Low Density Lipoprotein (LDL).</p><p>Atorvastatin reduces LDL-Cholesterol (LDL-C) and the number of LDL particles. Atorvastatin also reduces Very Low Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High Density Lipoprotein-Cholesterol (HDL-C). Elevated serum cholesterol due to elevated LDL-C is a major risk factor for the development of cardiovascular disease. Low serum concentration of HDL-C is also an independent risk factor.&nbsp; Elevated plasma TG is also a risk factor for cardiovascular disease, particularly if due to increased IDL, or associated with decreased HDL-C or increased LDL-C.</p><p>Epidemiologic, clinical and experimental studies have established that high LDL-C, low HDL-C and high plasma TG promote human atherosclerosis and are risk factors for developing cardiovascular disease.</p><p>Some studies have also shown that the total (TC):HDL-C ratio (TC:HDL-C) is the best predictor of coronary artery disease. In contrast, increased levels of HDL-C are associated with decreased cardiovascular risk. Drug therapies that reduce levels of LDL-C or decrease TG while simultaneously increasing HDL-C have demonstrated reductions in rates of cardiovascular mortality and morbidity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption: </strong>Atorvastatin is rapidly absorbed after oral administration; maximal plasma concentrations occur within 1 to 2 hours. Extent of absorption and plasma atorvastatin concentrations increase in proportion to atorvastatin dose. Atorvastatin tablets are 95-99% bioavailable compared to solutions. The absolute bioavailability (parent drug) of atorvastatin is approximately 12% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or first-pass metabolism in the liver. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, as assessed by Cmax and AUC respectively, LDL-C reduction and HDL-C elevation are similar when atorvastatin is given with and without food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax&nbsp;and AUC) following drug administration in the evening compared with morning dosing.</p><p>However, LDL-C reduction and HDL-C elevation are the same regardless of the time of drug administration.</p><p>&nbsp;</p><p><strong>Distribution: </strong>Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is &ge;98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin is likely to be secreted in human milk.</p><p>&nbsp;</p><p><strong>Metabolism: </strong>Atorvastatin is extensively metabolized to ortho- and para-hydroxylated derivatives by cytochrome P-450 3A4 (CYP 3A4) and to various beta-oxidation products. In vitro, inhibition of HMG- CoA reductase by ortho- and para-hydroxylated metabolites is equivalent to that of atorvastatin.</p><p>Approximately 70% of circulating inhibitory activity for HMG- CoA reductase is attributed to active metabolites. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation. Atorvastatin and its metabolites are eliminated by biliary excretion.</p><p>&nbsp;</p><p><strong>Excretion: </strong>Atorvastatin is eliminated primarily in bile following hepatic and/or extrahepatic metabolism; however, the drug does not appear to undergo significant enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life for inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of longer-lived active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.</p><p>&nbsp;</p><p><strong><u>Special Populations and Conditions</u></strong></p><p><strong>Pediatrics: </strong>Assessment of pharmacokinetic parameters such as Cmax, AUC and bioavailability of atorvastatin in pediatric patients (&gt;10 to &lt;17 years old, postmenarche) was not performed during the 6- month, placebo-controlled trial referred to earlier (see Clinical Studies - Heterozygous Familial Hypercholesterolemia in Pediatric Patients and PRECAUTIONS - Pediatric Use).</p><p>&nbsp;</p><p><strong>Geriatrics: </strong>Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax&nbsp;and 30% for AUC) in healthy elderly subjects (age 65 years or older) compared with younger individuals. LDL-C reduction, however, is comparable to that seen in younger patient populations.</p><p>&nbsp;</p><p><strong>Gender: </strong>Plasma concentrations of atorvastatin in women differ (approximately 20% higher for Cmax&nbsp;and 10% lower for AUC) from those in men; however, there is no clinically significant difference in LDL-C reduction between men and women.</p><p>&nbsp;</p><p><strong>Race:&nbsp;</strong>Plasma concentrations of atorvastatin are similar in black and white subjects.</p><p>&nbsp;</p><p><strong>Hepatic Insufficiency: </strong>Plasma concentrations of atorvastatin are markedly increased (approximately 16- fold in Cmax&nbsp;and 11-fold in AUC) in patients with chronic alcoholic liver disease (Childs-Pugh B).</p><p>&nbsp;</p><p><strong>Renal Insufficiency: </strong>Plasma concentrations and LDL-C lowering efficacy of atorvastatin are similar in patients with moderate renal insufficiency compared with patients with normal renal function. However, since several cases of rhabdomyolysis have been reported in patients with a history of renal insufficiency of unknown severity, as a precautionary measure and pending further experience in renal disease, the lowest dose (10 mg/day) of atorvastatin should be used in these patients. Similar precautions apply in patients with severe renal insufficiency [creatinine clearance &lt;30 mL/min (&lt;0.5 mL/sec)]; the lowest dosage should be used and implemented cautiously (see WARNINGS AND PRECAUTIONS, Muscle Effects; INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION; DOSAGE AND ADMINISTRATION).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Acute Toxicity</u></p><p>The acute toxicity of atorvastatin following single doses was evaluated in mice, rats and dogs by oral and intravenous routes, and the results are summarized below:</p><p>&nbsp;</p><p><strong>Table 20: &nbsp;Acute Oral and Intravenous Toxicity Studies with Atorvastatin</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Species</strong></p></td><td><p><strong>Sex</strong></p></td><td><p><strong>Route</strong></p></td><td><p><strong>Dose Range (mg/kg)</strong></p></td><td><p><strong>Results</strong></p></td></tr><tr><td><p>Mouse</p></td><td><p>Male/Female</p></td><td><p>Oral</p></td><td><p>200-5000</p></td><td><p>No Deaths</p></td></tr><tr><td><p>Mouse</p></td><td><p>Male/Female</p></td><td><p>IV</p></td><td><p>0.4-4</p></td><td><p>No Deaths</p></td></tr><tr><td><p>Rat</p></td><td><p>Male/Female</p></td><td><p>Oral</p></td><td><p>200-5000</p></td><td><p>No Deaths</p></td></tr><tr><td><p>Rat</p></td><td><p>Male/Female</p></td><td><p>IV</p></td><td><p>0.4-4</p></td><td><p>No Deaths</p></td></tr><tr><td><p>Dog</p></td><td><p>Male/Female</p></td><td><p>Oral</p></td><td><p>10-400</p></td><td><p>No Deaths</p></td></tr><tr><td><p>Dog</p></td><td><p>Male/Female</p></td><td><p>IV</p></td><td><p>0.4-4</p></td><td><p>No Deaths</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The acute toxicity of atorvastatin in rodents and dogs is low. Oral median lethal doses in mice and rats are greater than 5000 mg/kg.</p><p>&nbsp;</p><p><u>Subacute and Chronic Toxicity Studies</u></p><p>The target organs affected by atorvastatin in multiple dose toxicity studies in rats (2 weeks to 52 weeks), and dogs (2 weeks to 104 weeks) are summarized in the table below. The spectrum of effects observed is not unexpected in view of the magnitude of the dose levels used, potency of atorvastatin in inhibiting mevalonate synthesis and the essential role of HMG-CoA reductase in maintaining cellular homeostasis.</p><p>&nbsp;</p><p><strong>Table 21: Atorvastatin: Target Organs Affected in Animal Studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Rat</strong></p></td><td><p><strong>Dog</strong></p></td></tr><tr><td><p>Liver</p><p>Stomach (non-glandular)</p><p>Skeletal Muscle</p></td><td><p>Liver</p><p>Gallbladder</p><p>Skeletal</p><p>Muscle</p><p>Intestine</p><p>Brain/Optic Nerve*</p></td></tr></tbody></table><p>* Occurred after administration of high, intolerable doses (280 mg/kg)</p><p>&nbsp;</p><p>The following table summarizes the significant adverse changes observed during long-term toxicology studies in rats (52 weeks) and dogs (104 weeks):</p><p>&nbsp;</p><p><strong>Table 22: Atorvastatin: Significant Adverse Changes in Chronic Studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Species/Results</strong></p></td><td><p><strong>Minimal</strong><strong> </strong><strong>Toxic</strong><strong> </strong><strong>Dose</strong></p><p><strong>(mg/kg/day)</strong></p></td><td><p><strong>No-Effect Dose (mg/kg/day)</strong></p></td></tr><tr><td colspan="3"><p><strong>RAT</strong></p></td></tr><tr><td><p>Hepatocellular atypia</p></td><td><p>70</p></td><td><p>5</p></td></tr><tr><td><p>Bile duct hyperplasia (1)</p></td><td><p>125</p></td><td><p>70</p></td></tr><tr><td><p>Nonglandular stomach acanthosis</p></td><td><p>125</p></td><td><p>70</p></td></tr><tr><td colspan="3"><p><strong>DOG</strong></p></td></tr><tr><td><p>Death (2)</p></td><td><p>120</p></td><td><p>40</p></td></tr><tr><td><p>Hepatocellular granulomata (3)</p></td><td><p>10</p></td><td><p>ND</p></td></tr><tr><td><p>Hepatocellular necrosis (3)</p></td><td><p>120</p></td><td><p>40</p></td></tr><tr><td><p>Gallbladder edema/hemorrhage (3)</p></td><td><p>120</p></td><td><p>40</p></td></tr><tr><td><p>Bile duct hyperplasia (3)</p></td><td><p>120</p></td><td><p>10</p></td></tr><tr><td><p>Intestinal ulcers and single cell necrosis (3)</p></td><td><p>120</p></td><td><p>40</p></td></tr><tr><td><p>Skeletal muscle (tongue) necrosis (2)</p></td><td><p>120</p></td><td><p>40</p></td></tr></tbody></table><p>(1) Present only at Week 26; not observed at Week 52.</p><p>(2) Findings occurred in Week 7 or 9.</p><p>(3) Findings occurred at Week 52 or in moribund dogs, were less pronounced after a 12-week withdrawal period (Week 64), and were not observed after 104 weeks of dosing.</p><p>ND = Not determined.</p><p>&nbsp;</p><p>The results of the long-term toxicology studies with atorvastatin indicated that similar to other HMG-CoA reductase inhibitors, the liver is the primary target organ. This is expected since the liver is the primary site of the pharmacologic action of atorvastatin and it is subject to the greatest drug exposure following oral administration. In both the rat and dog studies, the hepatic changes diminished with time (i.e. effects were less pronounced at the end of the 52-week and 104-week studies) suggesting an adaptive response.</p><p>Brain hemorrhage, optic nerve degeneration, lenticular opacities and testicular degeneration were not seen in dogs treated for 104-weeks with atorvastatin up to 120 mg/kg/day. <u>Carcinogenicity and Genotoxicity Studies</u></p><p>Atorvastatin was not carcinogenic in rats given 10, 30 or 100 mg/kg/day for 2 years. The 100 mg/kg dose is 63-fold higher than the maximum recommended human dose of 80 mg (1.6 mg/kg, based on a 50 kg human) and AUC (0-24 hr) values were 8-to 16-fold higher.</p><p>In a 2-year study in mice given 100, 200 or 400 mg/kg/day, incidences of hepatocellular adenoma in &nbsp;males and hepatocellular carcinoma in females were increased at 400 mg/kg. This dose is 250 times the maximum recommended human dose on a mg/kg basis and systemic exposure based on AUC (0-24 hr) was 6 to 11 times higher. There was no evidence of treatment-related increases in tumor incidences at the lower doses of 100 and 200 mg/kg/day (i.e. up to 125 times the maximum recommended human dose on a mg/kg basis and systemic exposures of 3 times higher based on AUC (0-24 hr).</p><p>Atorvastatin did not demonstrate mutagenic or clastogenic potential in four in vitro tests with and without metabolic activation or in one in vivo assay. It was negative in the Ames test with <em>Salmonella typhimurium </em>and <em>Escherichia coli</em>, and in the in vitro HGPRT forward mutation assay in Chinese hamster lung cells. Atorvastatin did not produce significant increases in chromosomal aberrations in the in vitro Chinese hamster lung cell assay and was negative in the in vivo mouse micronucleus test.</p><p>&nbsp;</p><p><u>Reproductive and Teratogenicity Studies</u></p><p>No adverse effects on fertility or reproduction were observed in male rats given doses of atorvastatin up &nbsp;to 175/mg/kg/day or in female rats given doses up to 225 mg/kg/day. These doses are 100 to 140 times &nbsp;the maximum recommended human dose on a mg/kg basis. Atorvastatin did not cause any adverse effects on sperm or semen parameters, or in reproductive organ histopathology in dogs given doses of 10, 40 or 120 mg/kg for 2 years. Atorvastatin was not teratogenic in either rats or rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Name</strong><strong> of the excipients(s)</strong></p></td></tr><tr><td><p>Calcium Acetate</p></td></tr><tr><td><p>Croscarmellose Sodium</p></td></tr><tr><td><p>Sodium Carbonate Anhydrous</p></td></tr><tr><td><p>Microcrystalline Cellulose PH102</p></td></tr><tr><td><p>Magnesium Stearate Vegetable Source</p></td></tr><tr><td><p>Colloidal Silicon Dioxide</p></td></tr><tr><td><p>Hydroxypropyl Methylcellulose 2910 E5</p></td></tr><tr><td><p>Hydroxypropyl Cellulose Type LF</p></td></tr><tr><td><p>Polyethylene Glycol 8000</p></td></tr><tr><td><p>Titanium Dioxide</p></td></tr><tr><td><p>Purified Water</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                21 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu/Alu blister (Silver cold form foil and silver plain foil) pack.</p><p>10 mg: Available in bottles of 90, 100, 500, and 1000 tablets, blisters of 30.</p><p>20 mg: Available in bottles of 90, 100, 500, and 1000 tablets, blisters of 30.</p><p>40 mg: Available in bottles of 90, 100, 500, and 1000 tablets, blisters of 30.</p><p>80 mg: Available in bottles of 90, 100 and 500 tablets, blisters of 30. Not all packs sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>